Can Tuzer1, Pelin Karadag1, Ozan Yegit1, Deniz Eyice1, Nida Oztop1, Ali Can1, Semra Demir1, Raif Coskun2, Derya Erdogdu Unal3, Muge Olgac4, Suna Buyukozturk1, Bahattin Colakoglu1, Aslı Gelincik1. 1. From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 2. Adult Immunology and Allergy Clinic, Okmeydanı Education and Research Hospital, Istanbul, Turkey. 3. Adult Immunology and Allergy Clinic, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey; and. 4. Adult Immunology and Allergy Clinic, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.
Abstract
Background: The clinical effects of intranasal corticosteroids (INC) on nasal symptoms and the clinical course of coronavirus disease 2019 (COVID-19) in subjects with chronic rhinitis (CR) seem unclear. Objective: To evaluate the clinical effects of INCs on nasal symptoms in subjects with CR and with COVID-19. Methods: In subjects with CR and diagnosed with COVID-19 at four tertiary centers, quality of life and nasal symptoms were assessed by using the 22-item Sino-Nasal Outcome Test (SNOT-22) and the visual analog scale (VAS), respectively. In subjects with allergic rhinitis, nasal symptoms were also assessed on the total symptom score-6 (TSS-6) scale. The subjects were then allocated into two groups according to whether or not they used INCs while infected with the severe acute respiratory syndrome coronavirus 2 (group 1 and group 2, respectively). The subjects in group 2 were divided into two subgroups according to the use of antihistamines and/or leukotriene receptor antagonist or not (group 2a and group 2b, respectively). All the scores were compared before and during COVID-19 among the three groups. Results: A total of 71 subjects (21 in group 1, 24 in group 2a, and 26 in group 2b) were enrolled. The total scores of the SNOT-22 increased remarkably in all the groups during the infection when compared with the pre-COVID-19 scores (p < 0.001 in each group). However, the difference between the pre-COVID-19 and COVID-19 values revealed a lower decrease in the senses of smell and/or taste in group 1 than in group 2a and group 2b (p = 0.015, adjusted p = 0.045; and p = 0.001, adjusted p = 0.002, respectively). There were no significant differences in other COVID-19 findings, VAS, and TSS-6 scores among the groups (all p > 0.05). Conclusion: INCs in subjects with CR seemed protective against the decrease in smell and/or taste observed during COVID-19 and do not aggravate the clinical course of COVID-19.
Background: The clinical effects of intranasal corticosteroids (INC) on nasal symptoms and the clinical course of coronavirus disease 2019 (COVID-19) in subjects with chronic rhinitis (CR) seem unclear. Objective: To evaluate the clinical effects of INCs on nasal symptoms in subjects with CR and with COVID-19. Methods: In subjects with CR and diagnosed with COVID-19 at four tertiary centers, quality of life and nasal symptoms were assessed by using the 22-item Sino-Nasal Outcome Test (SNOT-22) and the visual analog scale (VAS), respectively. In subjects with allergic rhinitis, nasal symptoms were also assessed on the total symptom score-6 (TSS-6) scale. The subjects were then allocated into two groups according to whether or not they used INCs while infected with the severe acute respiratory syndrome coronavirus 2 (group 1 and group 2, respectively). The subjects in group 2 were divided into two subgroups according to the use of antihistamines and/or leukotriene receptor antagonist or not (group 2a and group 2b, respectively). All the scores were compared before and during COVID-19 among the three groups. Results: A total of 71 subjects (21 in group 1, 24 in group 2a, and 26 in group 2b) were enrolled. The total scores of the SNOT-22 increased remarkably in all the groups during the infection when compared with the pre-COVID-19 scores (p < 0.001 in each group). However, the difference between the pre-COVID-19 and COVID-19 values revealed a lower decrease in the senses of smell and/or taste in group 1 than in group 2a and group 2b (p = 0.015, adjusted p = 0.045; and p = 0.001, adjusted p = 0.002, respectively). There were no significant differences in other COVID-19 findings, VAS, and TSS-6 scores among the groups (all p > 0.05). Conclusion: INCs in subjects with CR seemed protective against the decrease in smell and/or taste observed during COVID-19 and do not aggravate the clinical course of COVID-19.
Authors: Alfred B Addison; Billy Wong; Tanzime Ahmed; Alberto Macchi; Iordanis Konstantinidis; Caroline Huart; Johannes Frasnelli; Alexander W Fjaeldstad; Vijay R Ramakrishnan; Philippe Rombaux; Katherine L Whitcroft; Eric H Holbrook; Sophia C Poletti; Julien W Hsieh; Basile N Landis; James Boardman; Antje Welge-Lüssen; Devina Maru; Thomas Hummel; Carl M Philpott Journal: J Allergy Clin Immunol Date: 2021-01-13 Impact factor: 10.793
Authors: Michael D Seidman; Richard K Gurgel; Sandra Y Lin; Seth R Schwartz; Fuad M Baroody; James R Bonner; Douglas E Dawson; Mark S Dykewicz; Jesse M Hackell; Joseph K Han; Stacey L Ishman; Helene J Krouse; Sonya Malekzadeh; James Whit W Mims; Folashade S Omole; William D Reddy; Dana V Wallace; Sandra A Walsh; Barbara E Warren; Meghan N Wilson; Lorraine C Nnacheta Journal: Otolaryngol Head Neck Surg Date: 2015-02 Impact factor: 3.497
Authors: Jan Hagemann; Gabrielle L Onorato; Marek Jutel; Cezmi A Akdis; Ioana Agache; Torsten Zuberbier; Wienczyslawa Czarlewski; Joaquim Mullol; Anna Bedbrook; Claus Bachert; Kazi S Bennoor; Karl-Christian Bergmann; Fulvio Braido; Paulo Camargos; Luis Caraballo; Victoria Cardona; Thomas Casale; Lorenzo Cecchi; Tomas Chivato; Derek K Chu; Cemal Cingi; Jaime Correia-de-Sousa; Stefano Del Giacco; Dejan Dokic; Mark Dykewicz; Motohiro Ebisawa; Yehia El-Gamal; Regina Emuzyte; Jean-Luc Fauquert; Alessandro Fiocchi; Wytske J Fokkens; Joao A Fonseca; Bilun Gemicioglu; René-Maximiliano Gomez; Maia Gotua; Tari Haahtela; Eckard Hamelmann; Tomohisa Iinuma; Juan Carlos Ivancevich; Ewa Jassem; Omer Kalayci; Przemyslaw Kardas; Musa Khaitov; Piotr Kuna; Violeta Kvedariene; Desiree E Larenas-Linnemann; Brian Lipworth; Michael Makris; Jorge F Maspero; Neven Miculinic; Florin Mihaltan; Yousser Mohammad; Stephen Montefort; Mario Morais-Almeida; Ralph Mösges; Robert Naclerio; Hugo Neffen; Marek Niedoszytko; Robyn E O'Hehir; Ken Ohta; Yoshitaka Okamoto; Kimi Okubo; Petr Panzner; Nikolaos G Papadopoulos; Giovanni Passalacqua; Vincenzo Patella; Ana Pereira; Oliver Pfaar; Davor Plavec; Todor A Popov; Emmanuel P Prokopakis; Francesca Puggioni; Filip Raciborski; Jere Reijula; Frederico S Regateiro; Sietze Reitsma; Antonino Romano; Nelson Rosario; Menachem Rottem; Dermot Ryan; Boleslaw Samolinski; Joaquin Sastre; Dirceu Solé; Milan Sova; Cristiana Stellato; Charlotte Suppli-Ulrik; Ioanna Tsiligianni; Antonio Valero; Arunas Valiulis; Erkka Valovirta; Tuula Vasankari; Maria Teresa Ventura; Dana Wallace; De Yun Wang; Siân Williams; Arzu Yorgancioglu; Osman M Yusuf; Mario Zernotti; Jean Bousquet; Ludger Klimek Journal: Allergy Date: 2021-05-14 Impact factor: 14.710
Authors: Lydia J Finney; Nicholas Glanville; Hugo Farne; Julia Aniscenko; Peter Fenwick; Samuel V Kemp; Maria-Belen Trujillo-Torralbo; Su Ling Loo; Maria Adelaide Calderazzo; Jadwiga A Wedzicha; Patrick Mallia; Nathan W Bartlett; Sebastian L Johnston; Aran Singanayagam Journal: J Allergy Clin Immunol Date: 2020-10-15 Impact factor: 10.793
Authors: P Herman; C Vincent; C Parietti Winkler; N Loundon; V Couloigner; F Tankere; S Tringali; P Gallet; J-F Papon; M Montava; J-P Lavieille; A Charpiot; S Schmerber Journal: Eur Ann Otorhinolaryngol Head Neck Dis Date: 2020-05-04 Impact factor: 2.080